Literature DB >> 21318986

Secondary pulmonary alveolar proteinosis in a patient with chronic myeloid leukemia in the accelerated phase.

Ken Ohmachi1, Daisuke Ogiya, Fujiko Morita, Minoru Kojima, Kosuke Tsuboi, Kei Tazume, Masamichi Komatsu, Naoki Hayama, Nobue Kumaki, Yoshiaki Ogawa, Kiyoshi Ando.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease the character of which is accumulation of protein consisting of surfactant in alveolar spaces. PAP sometimes complicates with hematological malignancies, especially myeloid leukemia. As one of the cause of PAP, impairment of alveolar macrophage is considered. We experienced a case of PAP with chronic myeloid leukemia (CML). 41 years old woman having CML for nine years developed PAP, and was treated by bronchoalveolar lavage and imatinib. She died of respiratory failure in the end, but BAL fluid had been becoming gradually crystalline after induction of imatinib. We consider that we should try to treat to improve respiratory status not only PAP but also hematological disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 21318986

Source DB:  PubMed          Journal:  Tokai J Exp Clin Med        ISSN: 0385-0005


  3 in total

Review 1.  GM-CSF Autoantibody-positive Pulmonary Alveolar Proteinosis with Simultaneous Myeloproliferative Neoplasm.

Authors:  Naoto Imoto; Nakashima Harunori; Katsuya Furukawa; Naoyuki Tange; Atsushi Murase; Masaya Hayakawa; Masatoshi Ichihara; Yosuke Iwata; Hiroshi Kosugi
Journal:  Intern Med       Date:  2017-02-15       Impact factor: 1.271

2.  Chronic myelomonocytic leukemia-associated pulmonary alveolar proteinosis: A case report and review of literature.

Authors:  Can Chen; Xi-Lian Huang; Da-Quan Gao; Yi-Wei Li; Shen-Xian Qian
Journal:  World J Clin Cases       Date:  2021-02-16       Impact factor: 1.337

3.  ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.

Authors:  Mariko Yoshimura; Kensuke Kojima; Rika Tomimasu; Noriyasu Fukushima; Shinichiro Hayashi; Eisaburo Sueoka; Shinya Kimura
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.